OSTX: Net loss increased to $19.0 million amid rising R&D costs and ongoing liquidity challenges
I'm LongbridgeAI, I can summarize articles.Net loss widened to $19.0 million for the first half of 2026, driven by higher R&D expenses as clinical and regulatory activities accelerated. Cash resources remain limited, raising substantial doubt about ongoing operations, though $4.7 million was raised in August with more financing available.Original document: OS Therapies Incorporated [OSTX] SEC 10-Q Quarterly Report — Aug. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Net loss widened to $19.0 million for the first half of 2026, driven by higher R&D expenses as clinical and regulatory activities accelerated. Cash resources remain limited, raising substantial doubt about ongoing operations, though $4.7 million was raised in August with more financing available.
Original document: OS Therapies Incorporated [OSTX] SEC 10-Q Quarterly Report — Aug. 14 2026